Archive: Company News
Company News: BioNTech Manufacturing Subsidiary, EUFETS, Becomes BioNTech Innovative Manufacturing Services
– Expansion and re-branding to ensure continued growth –
BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that its manufacturing subsidiary, EUFETS GmbH, has been re-branded as BioNTech Innovative Manufacturing Services. Furthermore, to prepare for further growth in response to increasing demand for cell and gene therapy products, in particular for CAR-T and T-Cell immunotherapies, BioNTech Innovative Manufacturing Services will significantly increase its production capacity by doubling cleanroom space and expanding development and quality control areas in a new facility.
Company News: Highly Sensitive Assessment Of Common Somatic Mutations In Pulmonary Non-Small Cell Carcinoma With The MassARRAY® System
Agena Bioscience today announced a comparative study published in PLOS ONE highlighting the use of its mass spectrometry-based platform and new, highly sensitive iPLEX® HS chemistry for detection of somatic mutations in EGFR, KRAS, BRAF, and NRAS occurring in non-small cell lung cancer (NSCLC).
Company News: MGI and Curetis to Collaborate on NGS-based Infectious Disease Diagnostics
– Broad collaboration to develop a targeted Next-Generation Sequencing assay for microbial infections
– Workflow for native samples integrating MGI and Curetis instrumentation
– Curetis’ subsidiary Ares Genetics to provide assay design and data interpretation app
Company News: Anergis Announces Top Line Results from Large-Scale ATIBAR Trial with Ultra-Fast Allergy Immunotherapy AllerT
– Primary endpoint met: Combined Symptom and Medication Score in the AllerT 50 µg group is 7% lower than in the placebo group (p = 0.0047) over the entire birch pollen season
– Rhinoconjunctivitis Symptom Score in the AllerT 50 µg group is 14% lower than in the placebo group (p < 0.0001)
– Nighttime Nasal Symptom Score in the AllerT 50 µg group is 35% lower than in the placebo group (p<0.0001)
– Asthma Symptom and Medication Score in the AllerT 50 µg group is 29% lower than in the placebo group (p<0.0001)